Study overview:
- Patients with a confirmed cancer diagnosis who initiated a new ADC therapy between January 1, 2020, and June 30, 2023.
- Patients were required to have at least a 12-month of continuous health plan enrollment prior to initiation (index date).
Main Outcomes and Measures:
- Primary outcome: all-cause mortality during at least 12 months of follow-up post-index.
- Secondary outcomes: included the time from cancer diagnosis to ADC initiation and the prevalence of secondary cancers.
- Kaplan-Meier methods were used to estimate survival.
- Cox proportional hazards models were used to assess mortality risk, adjusted for patient demographics, cancer type, and ADC agent.
The analysis highlights survival outcomes for patients treated with ADCs varied significantly according to the specific agent, cancer indication, and sociodemographic factors, including payer type.
These findings underscore the importance of patient selection and highlight existing variation in outcomes. Further research is needed to optimize the timing and application of ADC therapy in clinical practice.
See the full research poster below for more detail.